Dissecting current market conditions and the impact "rumormongers" have on trade, with Art Cashin of UBS, and CNBC's Bob Pisani.
"Street Signs" hosts Mandy Drury and Brian Sullivan look at 5 stocks with analyst recommendations, including mostly bullish analyst comments for the new Quorvo.
CNBC's Bob Pisani reports on stability in the markets.
CNBC's Rick Santelli reports the latest consumer sentiment data.
The legal overhang on banks seems wrong to me, says CNBC's Jim Cramer in discussing some of the challenges facing the big banks.
Is the market about to rollover? CNBC's Jim Cramer explains why he is watching biotech closely.
CNBC's Bob Pisani reports FXCM has halted trading, and digs into the performance of the energy and financial sectors.
CNBC's Bob Pisani reports from the FXCM post where trading has been halted. Pisani explains the brokerage firm's situation. CNBC's David Faber provides insight on the "black swan" event.
CNBC's Jim Cramer says no one is going to look at banks until the rates go higher.
Markets will see further degrees of elevated volatility if the European Central Bank does not step up to market expectations, Jeremy Stretch said.
Wall Street will pay even more attention than usual to Friday's consumer price index, or CPI.
U.S. stock futures were under pressure this morning, after a fifth session of declines on that stunning Swiss currency move, weaker U.S. economic data, and disappointing bank earnings.
Rick Hsu, Regional Head of Technology at Daiwa, explains his "buy" rating on the Taiwanese semiconductor foundry, with a target price of TWD $170.
The Swiss National Bank made a pre-emptive move ahead of next week's ECB meeting and that raises the pressure on ECB to implement its QE plans, says Mark Mobius, Executive Chairman of Templeton Emerging Markets Group.
Mad Money host Jim Cramer shares his opinion on the big time retailer after its announced moved away from Canada.
Charles Sizemore, CIO of Sizemore Capital Management, says profit-taking and gloomy market sentiment could have weighed on Intel's stock overnight.
JJ Bienaime, BioMarin Pharmaceuticals CEO, discusses the launch of Vimizim and the company's prospects, with Mad Money's Jim Cramer.
There is an overriding sense of anxiety over possible moves from the ECB and the Fed, which is stopping investors from buying the dip, says Kenny Polcari, Director of O'Neil Securities.
Amid global currency woes, Mad Money host Jim Cramer shares his view on why America is number 1.
What the FM traders' portfolios say about them, with CNBC.com's Eric Chemi.